Paik Julie J, Werth Victoria P, Chinoy Hector, Masri Karim R, Jambekar Amruta, Hasan Feza, Borlenghi Cecilia E, Gold David A
Division of Rheumatology, Johns Hopkins University, School of Medicine, Baltimore, MD, USA.
Division of Dermatology, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA.
Rheumatology (Oxford). 2025 Jun 1;64(6):3288-3302. doi: 10.1093/rheumatology/keaf116.
Myositis, or idiopathic inflammatory myopathy, encompasses a group of autoimmune diseases with broad-spectrum clinical presentations, with a common presentation of muscle weakness and inflammation. The management of myositis presents significant challenges due to the rarity and variability of the disease and lack of large-scale, randomized controlled trials. Due to limited evidence available from smaller studies as well as variation in treatment practices across geographical regions and disease subtypes, available published treatment recommendations vary significantly. There is a need, therefore, to develop multidisciplinary consensus-driven guidelines that appropriately reflect the diverse and complex nature of the disease. This comparative review presents an in-depth analysis of existing myositis treatment guidelines from diverse organizations, highlighting similarities and key differences in diagnoses, treatment and management recommendations. We propose that there is a need for developing globally unified, consensus-driven standardized set of guidelines for effective myositis management.
肌炎,即特发性炎性肌病,是一组临床表现广泛的自身免疫性疾病,常见表现为肌肉无力和炎症。由于该疾病罕见且多变,缺乏大规模随机对照试验,肌炎的治疗面临重大挑战。由于小型研究提供的证据有限,以及不同地理区域和疾病亚型的治疗方法存在差异,现有的已发表治疗建议差异很大。因此,需要制定多学科共识驱动的指南,以适当反映该疾病多样而复杂的性质。本比较综述对不同组织现有的肌炎治疗指南进行了深入分析,突出了诊断、治疗和管理建议方面的异同。我们认为,有必要制定一套全球统一、共识驱动的标准化指南,以有效管理肌炎。